Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction
Open Access
- 20 April 2024
- journal article
- research article
- Published by S. Karger AG in Obesity Facts
- Vol. 17 (4) , 347-354
Abstract
Introduction: Ultrasonography (US) in patients with obesity allows us to measure different layers of abdominal fat (superficial subcutaneous, deep subcutaneous, preperitoneal, omental, and perirenal), not assessable by DEXA or CT scan. Omental and perirenal fat depots are considered predictors of metabolic complications. Liraglutide is particularly effective in reducing weight in patients with insulin-resistance, but its direct impact on each abdominal fat layer is unknown. Methods: We measured, at the L4 level, all 5 abdominal fat depots in 860 patients with obesity (72.8% women, mean age 56.6 ± 1.5 years, BMI 34.4 ± 4.7 kg/m2, body fat 47 ± 2%, abdominal circumference 105.8 ± 3 cm), before and after 6 months of liraglutide treatment. Laboratory tests for glucose, insulin, and lipid profile were routinely done. T-student was used to compare intraindividual differences. Results: Weight loss was 7.5 ± 2.8 kg (7.96% from baseline), with no differences by sex/age/BMI. Greater loss was observed in patients with higher dosages and NAFLD. All US-measured fat layers showed a significant reduction (p < 0.05) at 6th months. Preperitoneal fat showed a −26 ± 5.5% reduction and 46% of the patients went below metabolic syndrome (MS) risk cut-off values. Omental fat was reduced by −17.8 ± 5% (67% of the patients below MS risk) and perirenal fat by −22.4 ± 4.4% (56% of the patients below MS). Both omental and perirenal fat reduction correlated with total and LDL cholesterol. Higher perirenal fat reduction (−28%) was seen among patients with obesity and hypertension. Perirenal fat also correlated with blood pressure reduction. Conclusion: Liraglutide induces greater fat loss in the layers involved with MS. However, the maximal reduction is seen at perirenal fat, which has been recently related with hypertension and could play an important role in modulating kidney’s expansion and intraglomerular pressure. US is a reproducible clinical tool to assess pathologic fat depots in patients living with obesity.Keywords
This publication has 32 references indexed in Scilit:
- MRI-based quantification of renal fat in obese individuals using different image analysis approachesAbdominal Radiology, 2022
- Evaluation and Management of Adults with Obstructive Sleep Apnea SyndromeLung, 2021
- Ultrasound measures of abdominal fat layers correlate with metabolic syndrome features in patients with obesityObesity Science & Practice, 2020
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without DiabetesJAMA, 2020
- Ultrasonography Technique in Abdominal Subcutaneous Adipose Tissue Measurement: A Systematic ReviewJournal of Ultrasound in Medicine, 2018
- Anatomical, Physiological, and Functional Diversity of Adipose TissueCell Metabolism, 2018
- Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2016
- Contrast-Enhanced Ultrasound: A Novel Noninvasive, Nonionizing Method for the Detection of Brown Adipose Tissue in HumansJournal of the American Society of Echocardiography, 2015
- Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patientsJournal of Medical Ultrasonics, 2015
- Sonographic evaluation of visceral fat by measuring para‐ and perirenal fatJournal of Clinical Ultrasound, 2007